Sartorius Stedim Biotech: Resolutions by the Board of Directors
February 21 2017 - 9:29AM
Business Wire
- Proposal to the Annual General
Shareholders’ Meeting to increase the dividend by 26.0% to €0.42
per share
- Adjustment of the structure and size
of the Board of Directors
Regulatory News:
The Board of Directors of Sartorius Stedim Biotech S.A.
(SSB) (Paris:DIM) resolved at its most recent meeting to
submit a proposal to the Annual General Shareholders' Meeting on
April 4, 2017, to pay a dividend for fiscal 2016 of €0.42 per
share. The previous year’s dividend, adjusted for the stock split
that was implemented in June 2016, was €0.33. Under this proposal,
the total profit distributed would rise from €30.7 million by 26.0%
to €38.7 million.
Within the framework of legal regulations in France, the Board
of Directors moreover decided to sharpen the allocation of
responsibilities between the Board and the company’s operational
management, reducing the Board’s size from ten to seven members.
Going forward, the SSB Board will consist of the following members:
Joachim Kreuzburg (Chairman), Susan Dexter, Anne-Marie Graffin,
Liliane de Lassus, Bernard Lemaître, Arnold Picot and Henri
Riey.
The former board members Volker Niebel, Oscar-Werner Reif and
Reinhard Vogt will remain fully in charge of their executive
responsibilities.
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of
products and services that enable the biopharmaceutical industry to
develop and manufacture drugs safely and efficiently. As a total
solutions provider, Sartorius Stedim Biotech offers a portfolio
covering nearly all steps of biopharmaceutical manufacture. The
company focuses on single-use technologies and value-added services
to meet the rapidly changing technology requirements of the
industry it serves. Headquartered in Aubagne, France, Sartorius
Stedim Biotech is quoted on the Eurolist of Euronext Paris. With
its own manufacturing and R&D sites in Europe, North America
and Asia and an international network of sales companies, Sartorius
Stedim Biotech has a global reach. In 2016, the company employed
approx. 4,700 people, and earned sales revenue of 1,051.6 million
euros.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170221005997/en/
Sartorius Stedim BiotechPetra Kirchhoff;Vice President of
Corporate CommunicationsPhone:
+49(0)551.308.1686petra.kirchhoff@sartorius.com
WisdomTree International... (AMEX:DIM)
Historical Stock Chart
From Nov 2024 to Dec 2024
WisdomTree International... (AMEX:DIM)
Historical Stock Chart
From Dec 2023 to Dec 2024